Chen Zhuo-chang, Ding Juan-juan, Qian Hao-yu, Lin Xiang-hua, Feng Ke-qing, Wang Jing
Department of Respiratory and Critical Care Medicine, Zhengzhou University, Zhengzhou, China.
Zhonghua Yi Xue Za Zhi. 2013 Apr 9;93(14):1076-9.
To explore the therapeutic efficacies of inhaled corticosteroids (ICS) plus low-dose theophylline for moderate bronchial asthma.
A total of 280 patients with moderate bronchial asthma at People's Hospital of Zhengzhou University between January 2011 and December 2011 were recruited and randomized into 2 groups: observation group with inhaled budesonide 400 µg/d plus aminophylline tablet (0.1 g, 3 times/day, oral administration and control group with inhaled budesonide 320 µg/day plus formoterol 9 µg/day. The course of treatment was around 6 months. The forced expiratory volume in one second % predicted (FEV1% predicted), interleukin (IL)-4, IL-5 and IgE of peripheral blood were compared before and after treatment.
Before and 6 months after treatment, the values of FEV1 % predicted, IL-4, IL-5 and IgE for the observed group were 68% ± 6% and 76% ± 6%, (14.5 ± 4.4) and (7.2 ± 2.6) ng/L, (27.4 ± 6.2) and (24.2 ± 5.9) ng/L, (771 ± 130) × 10(3) and(592 ± 104) × 10(3) U/L, respectively, while those for the control group were 66% ± 8% and 77% ± 6%, (13.7 ± 4.3) and (7.7 ± 4.0) ng/L, (26.9 ± 5.8) and (24.6 ± 4.8) ng/L, (752 ± 154) and (604 ± 122) × 10(3) U/L, respectively. There were significant improvements in both groups (all P < 0.05). No differences existed between two groups (all P > 0.05).
Compared with ICS plus inhaled long-acting β2-agonists (LABA), ICS plus low-dose theophylline shows similar efficacies in the improvement of lung function and the control of airway inflammation for asthmatics.
探讨吸入性糖皮质激素（ICS）联合小剂量茶碱治疗中度支气管哮喘的疗效。
选取2011年1月至2011年12月郑州大学人民医院收治的280例中度支气管哮喘患者，随机分为两组：观察组吸入布地奈德400μg/d加氨茶碱片（0.1g，每日3次，口服），对照组吸入布地奈德320μg/d加福莫特罗9μg/d。疗程约6个月。比较治疗前后一秒用力呼气容积占预计值百分比（FEV1%预计值）、外周血白细胞介素（IL）-4、IL-5和免疫球蛋白E（IgE）。
治疗前及治疗6个月后，观察组FEV1%预计值、IL-4、IL-5和IgE分别为68%±6%和76%±6%、（14.5±4.4）和（7.2±2.6）ng/L、（27.4±6.2）和（24.2±5.9）ng/L、（771±130）×10³和（592±104）×10³U/L，对照组分别为66%±8%和77%±6%、（13.7±4.3）和（7.7±4.0）ng/L、（26.9±5.8）和（24.6±4.8）ng/L、（752±154）和（604±122）×10³U/L。两组均有显著改善（均P<0.05）。两组间无差异（均P>0.05）。
与ICS联合吸入长效β2受体激动剂（LABA）相比，ICS联合小剂量茶碱在改善哮喘患者肺功能和控制气道炎症方面疗效相似。
